Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications
Several epidemiological studies have identified diabetes as a risk factor for colorectal cancer (CRC). The potential pathophysiological mechanisms of this association include hyperinsulinemia, insulin-like growth factor (IGF) axis, hyperglycemia, inflammation induced by adipose tissue dysfunction, g...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2022/1747326 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850209528175394816 |
|---|---|
| author | Guan-Hua Yu Shuo-Feng Li Ran Wei Zheng Jiang |
| author_facet | Guan-Hua Yu Shuo-Feng Li Ran Wei Zheng Jiang |
| author_sort | Guan-Hua Yu |
| collection | DOAJ |
| description | Several epidemiological studies have identified diabetes as a risk factor for colorectal cancer (CRC). The potential pathophysiological mechanisms of this association include hyperinsulinemia, insulin-like growth factor (IGF) axis, hyperglycemia, inflammation induced by adipose tissue dysfunction, gastrointestinal motility disorder, and impaired immunological surveillance. Several studies have shown that underlying diabetes adversely affects the prognosis of patients with CRC. This review explores the novel anticancer agents targeting IGF-1R and receptor for advanced glycation end products (RAGE), both of which play a vital role in diabetes-induced colorectal tumorigenesis. Inhibitors of IGF-1R and RAGE are expected to become promising therapeutic choices, particularly for CRC patients with diabetes. Furthermore, hypoglycemic therapy is associated with the incidence of CRC. Selection of appropriate hypoglycemic agents, which can reduce the risk of CRC in diabetic patients, is an unmet issue. Therefore, this review mainly summarizes the current studies concerning the connections among diabetes, hypoglycemic therapy, and CRC as well as provides a synthesis of the underlying pathophysiological mechanisms. Our synthesis provides a theoretical basis for rational use of hypoglycemic therapies and early diagnosis and treatment of diabetes-related CRC. |
| format | Article |
| id | doaj-art-9869a819f81f4e92a031950ec662b18d |
| institution | OA Journals |
| issn | 2314-6753 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-9869a819f81f4e92a031950ec662b18d2025-08-20T02:09:59ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/1747326Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic ImplicationsGuan-Hua Yu0Shuo-Feng Li1Ran Wei2Zheng Jiang3Department of Colorectal SurgeryDepartment of Colorectal SurgeryDepartment of Colorectal SurgeryDepartment of Colorectal SurgerySeveral epidemiological studies have identified diabetes as a risk factor for colorectal cancer (CRC). The potential pathophysiological mechanisms of this association include hyperinsulinemia, insulin-like growth factor (IGF) axis, hyperglycemia, inflammation induced by adipose tissue dysfunction, gastrointestinal motility disorder, and impaired immunological surveillance. Several studies have shown that underlying diabetes adversely affects the prognosis of patients with CRC. This review explores the novel anticancer agents targeting IGF-1R and receptor for advanced glycation end products (RAGE), both of which play a vital role in diabetes-induced colorectal tumorigenesis. Inhibitors of IGF-1R and RAGE are expected to become promising therapeutic choices, particularly for CRC patients with diabetes. Furthermore, hypoglycemic therapy is associated with the incidence of CRC. Selection of appropriate hypoglycemic agents, which can reduce the risk of CRC in diabetic patients, is an unmet issue. Therefore, this review mainly summarizes the current studies concerning the connections among diabetes, hypoglycemic therapy, and CRC as well as provides a synthesis of the underlying pathophysiological mechanisms. Our synthesis provides a theoretical basis for rational use of hypoglycemic therapies and early diagnosis and treatment of diabetes-related CRC.http://dx.doi.org/10.1155/2022/1747326 |
| spellingShingle | Guan-Hua Yu Shuo-Feng Li Ran Wei Zheng Jiang Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications Journal of Diabetes Research |
| title | Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications |
| title_full | Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications |
| title_fullStr | Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications |
| title_full_unstemmed | Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications |
| title_short | Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications |
| title_sort | diabetes and colorectal cancer risk clinical and therapeutic implications |
| url | http://dx.doi.org/10.1155/2022/1747326 |
| work_keys_str_mv | AT guanhuayu diabetesandcolorectalcancerriskclinicalandtherapeuticimplications AT shuofengli diabetesandcolorectalcancerriskclinicalandtherapeuticimplications AT ranwei diabetesandcolorectalcancerriskclinicalandtherapeuticimplications AT zhengjiang diabetesandcolorectalcancerriskclinicalandtherapeuticimplications |